ABSTRACT

FEN, LID, and BEP ................................................................................... 512 26.4 Drugs Affecting Adrenergic Nervous System and Other Antihypertensives....................... 512

26.4.1 In Situ Separation, Identication, and/or Determination of Alpha 1 Adrenoceptor ATs, Centrally Acting Sympatholytics, and Ganglion Blockers in Dosage Forms ........................................................................................................... 513

26.4.2 In Situ Separation, Identication, and/or Determination of Ganglion Blockers in Plants and Biological Fluids ................................................................................. 514

26.4.3 Other Classical and Newly Developed Options in TLC Screening .......................... 516 26.5 Endogenous Neurotransmitters and Their Synthetic Analogues ......................................... 517

26.5.1 In Situ Separation, Identication, and/or Determination of Catecholamines and Their Analogues in Bulk, Dosage Formulation, and Biological Fluids ................... 517

References ...................................................................................................................................... 520

In humans, blood volume and blood pressure are regulated by various physiological systems, mainly the components of the central and peripheral nervous systems, the hormonal systems, kidneys, the peripheral vascular network, etc. Certain abnormalities or diseases of these systems can create a hypertensive state in humans. An enhanced adrenergic activity is a principal contributor to the primary or essential hypertension, although the etiology of this type is not yet completely resolved (Mutschler and Derendorf 1995). Considering the complexity of all factors inuencing hypertension in humans, different chemical/pharmacological classes of drugs are used to treat them, namely, angiotensin converting enzyme (ACE) inhibitors; angiotensin receptor antagonists (ATs); calcium channel blockers; vasodilators (arterial, and arterial and venous); and adrenergics (centrally active sympatholytics, ganglion blockers, adrenergic neuron blockers, alpha adrenergic blockers, and others). In parallel with the high blood pressure, most often, the presence of certain other cardiovascular diseases occurs, which requires combination of certain drugs from the aforementioned groups with an additional therapy with diuretics and antilipidemics, and hence, apart from the monocomponent formulations, different multicomponent dosage formulations are launched nowadays as xed combination of drugs to treat hypertension (Williams 2008).